🏠 Take Home Messages from the early #axSpA session 🔺 Earlier diagnosis is possible and better 🔺 Early axSpA is not synonymous to mild 🔺 Longitudinally, early axSpA is heterogeneous 🔺 MRI has transformed the field ❗️Beware of pitfalls #EULAR2026 @RheumNow https://t.co/IhGQSxssyd

• https://x.com/Nellziade/status/2063396987253239928/photo/1
• https://x.com/Nellziade/status/2063396987253239928/photo/1
• https://x.com/Nellziade/status/2063396987253239928/photo/1
• https://x.com/Nellziade/status/2063396987253239928/photo/1

A high proportion of juvenile-onset SpA progress toward a r-axSpA phenotype Results from the Spanish REGISPON-3 POS1352 #EULAR2026 @RheumNow https://t.co/XicguAdXJ1

• https://x.com/Nellziade/status/2063265343502442821/photo/1

Is the risk of uveitis comparable between infliximab sc and adalimumab in patients with r-axSpA and prior AAU? Yes! POS 1347 Multicenter randomised open-label trial N=56 #EULAR2026 @RheumNow https://t.co/kP7ropPkpC

• https://x.com/Nellziade/status/2063267473172934848/photo/1

LB0001: Bimekizumab SUPERIOR to risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.0078). First ever H2H biologic superiority on joints in PsA. #Bimekizumab @RheumNow #EULAR2026 https://t.co/6waepYs9RK

• https://x.com/synovialjoints/status/2063217409222148317/photo/1

#EULAR2026 LB0001 BOLD results in #PsA. First H2H RCT showing superiority of Bimekizumab (IL17A- & F-i) vs Risankizumab (IL-23-i) in primary endpoint, ACR50 49% vs 38% at WK16. The difference was seen from WK4 & sustained to WK24. May help inform choice of Tx @RheumNow #EULARBest https://t.co/s4zbFiepuP

• https://x.com/Yuz6Yusof/status/2063217963818266828/photo/1

ACR50 at Week 4 was 19.9% (BKZ) vs 7.2% (RZB) nominal p<0.0001. Faster onset, higher sustained joint response. DAPSA LDA/remission 65% vs 55%. Dual IL-17A/F blockade outperforms IL-23 inhibition for joints in #PsA. Abstr LB0001 @RheumNow #EULAR2026 https://t.co/s4z8r1rKte

• https://x.com/synovialjoints/status/2063218464748179676/photo/1

First head-to-head trial to show #PsA joint outcome superiority BE BOLD: Bimekizumab (BKZ; IL-17A/F dual blockade) beat Risankizumab (RZB: IL-23i) on ACR50 at wk 16 (49.1% vs 38.4%, p=0.0078). BKZ also faster: ACR50 at wk 4 already 19.9% vs 7.2%. @RheumNow #EULAR2026 LB0001 https://t.co/YMQCpom5xD

• https://x.com/JihaRheum/status/2063218845842571488/photo/1

#EULAR2026 LB0002 More great news for dual IL17A and -F blockade. An open label Phase II study of Sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody'-3 in #axSpA: clinical efficacy, improvement in PROM and imaging inflammation. Looking forward to the RCT phase @RheumNow https://t.co/Xtxa8fALzN

• https://x.com/Yuz6Yusof/status/2063222743462481996/photo/1
• https://x.com/Yuz6Yusof/status/2063222743462481996/photo/1

LB0002: Sonelokimab (IL-17A/F Nanobody, ~40 kDa) in #axSpA Phase 2: 81% ASAS40 and 54% ASAS partial remission at 12 weeks. Mean ASDAS improvement of −2.0 from baseline. @RheumNow #EULAR2026 https://t.co/TjvtnFPCdj

• https://x.com/synovialjoints/status/2063219729972473914/photo/1

#OP0207 #EULAR2026: SUPERFIBRES trial suggests dietary fibre supplementation may enhance MTX response in RA. Inulin improved EULAR responses and Th17/Treg balance over 30 days, with strongest effects seen in MTX-treated patients. Fascinating microbiome-linked signal. @RheumNow https://t.co/nCvZlooamF

• https://x.com/DrMiniDey/status/2063174302157938957/photo/1

Key messages in the tx of ax/p-SpA: >csDMARDs only effective in pSpA >consider individualized treatment for bDMARDs and JAKis >Cycling TNFi equally effective to switching @RheumNow #EULAR2026 https://t.co/oeO3BxmYYo

• https://x.com/RHEUMarampa/status/2062911936103100779/photo/1